Stroke/Cerebrovascular Disease Perspective

 
 
  • Preeclampsia: Preventing Maternal Cardiovascular Events   Dr JoAnn Manson highlights temporal trends in the use of antihypertensive medications in women with preeclampsia and the risk for maternal stroke.
  • tPA in Stroke: 'The Facts Are Clear' Thrombolytic treatment for stroke remains controversial among specialties. Here, a neurologist argues for its use.
  • The Case Against Thrombolytic Therapy in Stroke A New York Times article siding with neurologists in their debate with emergency medicine over the benefits of tPA in ischemic stroke prompted Dr Mandrola to take a closer look at the data.
  • Which AFib Patients Should Receive Anticoagulation? Two clinicians discuss the newest approaches to risk scoring for bleeding and stroke in order to identify the patients who should receive anticoagulation.
  • Deprescribing Antipsychotics: New Algorithm Antipsychotics should only be used in very limited circumstances in elderly patients. Getting patients for whom they are not indicated off them is an important task. Here's how to do it.
  • Yosprala(TM) in At-Risk Patients Requiring Low-Dose Aspirin Do the benefits of Yosprala(TM) therapy outweigh its costs when compared with combination therapy with aspirin and a proton-pump inhibitor taken as individual products?
  • Will ODYSSEY Clear Hurdles for PCSK9 Inhibitor Access?   Drs Budoff and Baum discuss the topline results of the ODYSSEY trial presented at the 2018 ACC meeting and hope for easier access to PCSK9 inhibitors for their high-risk patients.
  • ACC 2018Sanjay Kaul Grades Four Big Trials From ACC 2018 Dr Kaul rates trials on alirocumab, black barbershop-based healthcare, canakinumab, and the wearable cardioverter defibrillator, from the 2018 American College of Cardiology Scientific Sessions.
  • Pharmacists and Barbers on the Cutting Edge of Medicine Dr Mandrola's hands-down favorite study from the 2018 American College of Cardiology meeting showed that a pharmacist-led intervention in black-owned barbershops cut hypertension in black men.
  • More Positives for PCSK9 inhibitors and the LDL-C Hypothesis   The co-investigator for the ODYSSEY study of alirocumab discusses which patients will benefit most from the expensive biologic and why the mortality reduction finding comes with qualifiers.
  • ACC 2018 MOMENTUM-3: The Future of the LVAD Is Here and Now A trial showing better outcomes for HeartMate 3 over HeartMate II sends Dr Walton-Shirley down memory lane to recall the patients she has referred for implantation of a left ventricular assist device (LVAD).
  • Updates in Stroke, Alzheimer's, Headache, and MS   Dr Diener on a month in neurology research characterized by failures--but also some gains.
  • What Did Cardiologists Learn Recently That PCPs Should Know? What are the five articles that cardiologists read in the last 12 months that may change primary care management of patients with cardiovascular disease?
  • Why Migraine? Why Now? Three leading clinicians discuss why this is an exciting time in migraine care.
  • How to Assess and Manage Stroke Risk in Atrial Fibrillation?   Drs Acharya, Friedman, and Klaas discuss when to anticoagulate patients with atrial fibrillation; additional factors that contribute to stroke risk; and treatment options for stroke prevention.
  • Listen Carefully During the Medical Interview   In this month's Critical Issues in Primary Care, Dr Fabrizia Faustinella describes two cases where critical listening during the patient history revealed 'red flags' that had been previously missed.
  • The State of the Art in Cardiovascular Risk Reduction Dr Williams provides an overview of the latest information on cardiovascular risk reduction, from the American College of Cardiology.
  • Mandrola Previews 2018 ACC PCSK9 inhibitors, LifeVest, and his-bundle pacing are among Dr Mandrola's picks for what to look for at the 2018 American College of Cardiology Scientific Sessions.
  • Migraine and Heart Disease: The Link Intensifies   Dr Arefa Cassoobhoy highlights a study that further links migraine and cardiovascular disease.
  • PPIs and CV Safety: Good Science to the Rescue Amid the controversy, Dr David Johnson reviews new research supporting the cardiovascular safety of PPIs.